@article{10.37349/etat.2023.00191,
abstract = {Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have shown impressive results in EGFR mutant lung cancer (LC) patients in terms of disease control rate with a positive impact on overall survival. Nevertheless, after months of treatment with targeted therapy, progression inevitably occurs. Some patients develop oligoprogression and local treatment is required for optimal disease control while maintaining EGFR-TKIs. This work features a clinical case of a patient harboring an EGFR mutant LC undergoing oligoprogression to EGFR-TKIs, first into the brain and afterward to the primary tumor, requiring local ablative strategies, including primary tumor resection three years after the start of osimertinib. Currently, the patient is still alive and continues with a complete response upon EGFR-TKIs maintenance. Hence, oligoprogression, even in driven oncogenic tumors, represents a distinct biological entity and potential curative disease that deserves particular consideration in multidisciplinary tumor boards. In this case, tumor primary resection after three years of the initial diagnosis represents a paradigm shift in the treatment of EGFR mutant patients.},
author = {Chekhun, Sviatoslav and Lopez-Paradís, Assumpció and Urbizu, Aintzane and Morán, Teresa and Mañes, Anabel and Cucurull, Marc and Martínez-Barenys, Carlos and Teruel, Iris and Moragas, Gloria and Carcereny, Enric and Muñoz Mármol, Ana Maria and Saigí, Maria},
doi = {10.37349/etat.2023.00191},
journal = {Exploration of Targeted Anti-tumor Therapy},
pages = {1182--1187},
title = {{Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma?}},
url = {https://www.explorationpub.com/Journals/etat/Article/1002191},
volume = {4},
year = {2023},
number = {6}
}